Objective: To investigate the effect of the Sheshang capsule on coagulation of the rabbits bitten by Trimeresurus stejnegeri and its mechanism.
Methods: The changes in platelet aggregation rate was observed after the establishment of rabbits model by subcutaneously injection with 0.75, 1.50, 2.25, and 3.00 mL/kg of Trimeresurus stejnegeri venom for 72 hours. Fifty New Zealand white rabbits were randomly divided into five groups, 10 rabbits in each group. Rabbit model was reproduced by subcutaneously injection with 0.75 mL/kg of Trimeresurus stejnegeri venom. The rabbits in sham group were injected with 0.75 mL/kg normal saline(NS). The rabbits were gavaged with 5, 10, 15 mL × kg⁻¹ × d⁻¹ of the Sheshang concoction to the low, intermediate and high dose groups respectively after 6 hours, and 10 mL × kg⁻¹ × d⁻¹ NS was fed in the sham group and model group. The platelet aggregation rate, platelet count (PLT), mean platelet volume (MPV), plateletcrit (PCT), platelet distribution width (PDW), cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA) were determined after 1 week.
Results: (1) With the increase in the concentration of Trimeresurus stejnegeri venom, 1-min, 3-min, 5-min and maximum platelet aggregation rates showed a gradual declining trends. (2) Compared with the sham group, 5-min and maximum platelet aggregation rate in the model group were significantly decreased [35.5 (24.2, 42.5)% vs. 43.0 (38.2, 58.5)%, 39.5 (29.0, 45.0)% vs. 46.5 (39.2, 60.2)%, both P<0.05]. Compared with the model group, 5-min and maximum platelet aggregation rate in the intermediate dose group were significantly increased [44.0 (39.8, 45.0) % vs. 35.5 (24.2, 42.5) %, 45.5 (43.5, 46.2) % vs. 39.5 (29.0, 45.0) %, both P<0.05]. There was no significant difference in platelet aggregation rate among the other groups. Compared with the sham group, PLT count in model group was obviously reduced (410.3 ± 155.3 × 10⁹/L vs. 724.5 ± 220.7 × 10⁹/L, P<0.01), so as MPV and PCT done [MPV: 5.11 ± 1.09 fl vs. 6.34 ± 1.16 fl, P<0.01; PCT: 21.9 (18.6, 26.8) % vs. 34.8 (24.8, 45.4) %, P<0.05]. Compared with the model group, PLT and PCT in the low, intermediate and high dose groups were significantly increased [PLT: 702.4 ± 166.3 × 10⁹/L, 648.5 ± 160.2 × 10⁹/L, 789.3 ± 86.2 × 10⁹/L vs. 410.3 ± 155.3 × 10⁹/L, PCT: 38.8 (35.7, 42.9)%, 36.0 (29.8, 44.4)%, 43.1 (40.5, 48.8)% vs. 21.9 (18.6, 26.8)%, all P<0.01], and MPV in the intermediate dose group was significantly increased (6.26 ± 1.05 fl vs. 5.11 ± 1.09 fl, P<0.01). There was no significant difference in PDW among groups (P>0.05). Compared with the sham group, cAMP (47.57 ± 12.76 nmol/L vs. 36.67 ± 10.54 nmol/L) and PKA (14.68 ± 5.80 μg/L vs. 9.23 ± 4.05 μg/L) in the model group were significantly increased (both P<0.05). Compared with the model group, cAMP and PKA of each dose group were decreased, while cAMP in low dose group [(36.33 ± 11.08) nmol/L] and PKA in the intermediate dose group [(10.21 ± 5.31) μg/L] were significant decreased (both P<0.05).
Conclusions: In the range of experimental concentration (0-3 mL/kg), the higher the concentration, and the stronger the inhibition of platelet aggregation rate was. The Sheshang capsule can raise platelet aggregation rate and PLT, increase MPV and PCT, and act against inhibition of platelet aggregation effect of the venom, thus improve the haemostatic function of platelet. Sheshang capsule can be used to treat the coagulopathy induced by Trimeresurus stejnegeri venom through regulating cAMP/PKA pathways.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3760/cma.j.issn.2095-4352.2014.08.013 | DOI Listing |
Clin Toxicol (Phila)
October 2024
National Defense Medical Center, Taipei, Taiwan.
Am J Trop Med Hyg
July 2024
PhD Program in Medical Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
In Taiwan, six medically important venomous snakes, Trimeresurus stejnegeri stejnegeri, Protobothrops mucrosquamatus, Deinagkistrodon acutus, Daboia siamensis, Naja atra, and Bungarus multicinctus, are found. However, comprehensive research on the complications and associated healthcare costs of snakebite envenomation (SBE) is lacking. We retrospectively analyzed pertinent information from the Taiwan National Health Insurance Research Database dated January 2002 to December 2014.
View Article and Find Full Text PDFPLoS Negl Trop Dis
March 2024
Department of Biological Science and Technology, National Pingtung University of Science and Technology, Pingtung, Taiwan.
Snakebite envenomation is a significant global health issue that requires specific antivenom treatments. In Taiwan, available antivenoms target a variety of snakes, but none specifically target Trimeresurus gracilis, an endemic and protected species found in the high mountain areas of Taiwan. This study evaluated the effectiveness of existing antivenoms against T.
View Article and Find Full Text PDFMicroorganisms
January 2024
Department of Computer Science and Engineering, National Sun Yat-sen University, Kaohsiung 804201, Taiwan.
The oral cavity of snakes serves as a habitat for various microorganisms, some of which may include potential zoonotic pathogens posing risks to hosts and causing wound infections in snakebite victims. Clinical studies on snakebite cases in Taiwan have identified specific pathogens, such as (Gram-positive), , , and (Gram-negative). However, the prevalence of these bacteria in the oral cavity of wild snakes remains largely unknown.
View Article and Find Full Text PDFAm J Trop Med Hyg
February 2024
Department of Emergency Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
Snakebite envenomation is a neglected tropical disease. Taiwan, with its subtropical and Southeast Asian environment, provides suitable habitat for several venomous snake species. Trimeresurus stejnegeri, an arboreal pit viper, is the most common cause of venomous snakebite in Taiwan.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!